Pay in 4 interest-free payments of $6.24 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
But the authors of this analysis are hoping to use it as the foundation for future clinical trials
You get clear guidance, simple check-ins, and a realistic path forward
Over 75% of health plans and over 50% of employers are moderately or very concerned about off-label use of GLP-1s approved for type 2 diabetes, but awareness of how much current spend is off-label is notably lower: nearly half of employers and a quarter of health plans are unsure
Presented for research literature review only Brown-Borg HM (2022)
Patients who used Zepbound for 36 weeks lost an average of 21%, but then, when switched to a placebo, after 1 year, they had regained 14% of their weight back
US$ 24.74
US$ 27.80
US$ 21.32
